Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Research Article

Modeling the Antiviral Activity of Ginkgo biloba Polyphenols against Variola: In Silico Exploration of Inhibitory Candidates for VarTMPK and HssTMPK Enzymes

Author(s): Hamdani Sarra, Bouchentouf Salim* and Allali Hocine

Volume 21, Issue 1, 2024

Published on: 10 October, 2023

Article ID: e101023221938 Pages: 35

DOI: 10.2174/0115701638261541230922095853

Price: $65

Abstract

Background: The aim of this study is to use modeling methods to estimate the antiviral activity of natural molecules extracted from Ginkgo biloba for the treatment of variola which is a zoonotic disease posing a growing threat to human survival. The recent spread of variola in nonendemic countries and the possibility of its use as a bioterrorism weapon have made it a global threat once again. Therefore, the search for new antiviral therapies with reduced side effects is necessary.

Methods: In this study, we examined the interactions between polyphenolic compounds from Ginkgo biloba, a plant known for its antiviral activity, and two enzymes involved in variola treatment, VarTMPK and HssTMPK, using molecular docking.

Results: The obtained docking scores showed that among the 152 selected polyphenolic compounds; many ligands had high inhibitory potential according to the energy affinity. By considering Lipinski’s rules, we found that Liquiritin and Olivil molecules are the best candidates to be developed into drugs that inhibit VarTMPK because of their high obtained scores compared to reference ligands, and zero violations of Lipinski’s rules. We also found that ginkgolic acids have good affinities with HssTMPK and acceptable physicochemical properties to be developed into drugs administered orally.

Conclusion: Based on the obtained scores and Lipinski’s rules, Liquiritin, Olivil, and ginkgolic acids molecules showed interesting results for both studied enzymes, indicating the existence of promising and moderate activity of these polyphenols for the treatment of variola and for possible multi-targeting. Liquiritin has been shown to exhibit anti-inflammatory effects on various inflammation- related diseases such as skin injury, hepatic inflammatory injury, and rheumatoid arthritis. Olivil has been shown to have antioxidant activity. Olivil derivatives have also been studied for their potential use as anticancer agents. Ginkgolic acids have been shown to have antimicrobial and antifungal properties. However, ginkgolic acids are also known to cause allergic reactions in some people. Therefore, future studies should consider these results and explore the potential of these compounds as antiviral agents. Further experimental studies in-vitro and in-vivo are required to validate and scale up these findings.

Graphical Abstract

[1]
Je Z, Khodakevich ILN, Wickett’ JF. Smallpox and its post-eradication surveillance. Bull World Health Organ 1987; 65(4): 425-34.
[2]
Guimarães AP, Ramalho TC, França TCC. Preventing the return of smallpox: Molecular modeling studies on thymidylate kinase from Variola virus. J Biomol Struct Dyn 2014; 32(10): 1601-12.
[http://dx.doi.org/10.1080/07391102.2013.830578] [PMID: 23998201]
[3]
Garcia DR, Souza FR, Guimarães AP, et al. In silico studies of potential selective inhibitors of thymidylate kinase from Variola virus. Pharmaceuticals 2021; 14(10): 1027.
[http://dx.doi.org/10.3390/ph14101027] [PMID: 34681251]
[4]
Babkin I, Babkina I. The origin of the variola virus. Viruses 2015; 7(3): 1100-12.
[http://dx.doi.org/10.3390/v7031100] [PMID: 25763864]
[5]
Weir E. Does smallpox still pose a threat? CMAJ 2001; 165(10): 1380.
[PMID: 11760991]
[6]
Thèves C, Biagini P, Crubézy E. The rediscovery of smallpox. Clin Microbiol Infect 2014; 20(3): 210-8.
[http://dx.doi.org/10.1111/1469-0691.12536] [PMID: 24438205]
[7]
Rodrigues Garcia D, Rodrigues de Souza F, Paula Guimarães A, Castro Ramalho T, Palermo de Aguiar A, Celmar Costa França T. Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox: part II. J Biomol Struct Dyn 2019; 37(17): 4569-79.
[http://dx.doi.org/10.1080/07391102.2018.1554510] [PMID: 30488769]
[8]
Almehmadi M, Allahyani M, Alsaiari AA, et al. A glance at the development and patent literature of tecovirimat: The first-in-class therapy for emerging monkeypox outbreak. Viruses 2022; 14(9): 1870.
[http://dx.doi.org/10.3390/v14091870] [PMID: 36146675]
[9]
Chakraborty C, Bhattacharya M, Sharma AR, Dhama K. Evolution, epidemiology, geographical distribution, and mutational landscape of newly emerging monkeypox virus. Geroscience 2022; 44(6): 2895-911.
[http://dx.doi.org/10.1007/s11357-022-00659-4] [PMID: 36094771]
[10]
Petersen E, Kantele A, Koopmans M, et al. Human monkeypox. Infect Dis Clin North Am 2019; 33(4): 1027-43.
[http://dx.doi.org/10.1016/j.idc.2019.03.001] [PMID: 30981594]
[11]
Statement by the Director-General of WHO at the press conference following the International Health Regulations Emergency Committee regarding the multi-country outbreak of simian orthopoxvirus (monkey pox). Available from: https://www.who.int/fr/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022 (23 July 2022).
[12]
Musa-Booth TO, Medugu N, Adegboro B, Babazhitsu M. A review of the epidemiology, diagnosis, treatment, vaccines and economic impact of human monkeypox (Mpox) outbreaks. Afr J Clin Exp Microbiol 2023; 24: 1-8.
[13]
Thakur M, Das P, Sobti RC, Kaur T. Human monkeypox: Epidemiology, transmission, pathogenesis, immunology, diagnosis and therapeutics. Mol Cell Biochem 2023; 478(9): 2097-110.
[http://dx.doi.org/10.1007/s11010-022-04657-0] [PMID: 36626099]
[14]
Gercek Z, Jumamyradova S, Senturk AM. The synthesis and docking study of novel compounds for variola virus. Europ J Adv Chem Res 2022; 3: 1-7.
[http://dx.doi.org/10.24018/ejchem.2022.3.2.96]
[15]
Merchlinsky M, Albright A, Olson V, et al. The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox. Antiviral Res 2019; 168: 168-74.
[http://dx.doi.org/10.1016/j.antiviral.2019.06.005] [PMID: 31181284]
[16]
Chan-Tack KM, Harrington PR, Choi SY, et al. Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox. Lancet Infect Dis 2019; 19(6): e221-4.
[http://dx.doi.org/10.1016/S1473-3099(18)30788-6] [PMID: 30853252]
[17]
Russo AT, Berhanu A, Bigger CB, et al. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine 2020; 38(3): 644-54.
[http://dx.doi.org/10.1016/j.vaccine.2019.10.049] [PMID: 31677948]
[18]
Mohapatra RK, Mishra S, Rabaan AA, Mohanty A, Padhi BK, Sah R. Monkeypox breakthrough infections and side-effects: Clarion call for nex-gen novel vaccine. New Microbes New Infect 2023; 52: 101084.
[http://dx.doi.org/10.1016/j.nmni.2023.101084] [PMID: 36694837]
[19]
Prevention and treatment of monkeypox. Med Lett Drugs Ther 2022; 64(1658): 137-9.
[PMID: 36094551]
[20]
Sah R, Paul D, Mohanty A, Shah A, Mohanasundaram AS, Padhi BK. Monkeypox (Mpox) vaccines and their side effects: The other side of the coin. Int J Surg 2023; 109(2): 215-7.
[http://dx.doi.org/10.1097/JS9.0000000000000142] [PMID: 36799858]
[21]
Young RJ, Flitsch SL, Grigalunas M, et al. The time and place for nature in drug discovery. JACS Au 2022; 2: 2400-16.
[http://dx.doi.org/10.1021/jacsau.2c00415]
[22]
Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients 2010; 2(12): 1231-46.
[http://dx.doi.org/10.3390/nu2121231] [PMID: 22254006]
[23]
Fraga CG, Croft KD, Kennedy DO, Tomás-Barberán FA. The effects of polyphenols and other bioactives on human health. Food Funct 2019; 10(2): 514-28.
[http://dx.doi.org/10.1039/C8FO01997E] [PMID: 30746536]
[24]
Luca SV, Macovei I, Bujor A, et al. Bioactivity of dietary polyphenols: The role of metabolites. Crit Rev Food Sci Nutr 2020; 60(4): 626-59.
[http://dx.doi.org/10.1080/10408398.2018.1546669] [PMID: 30614249]
[25]
Qa’dan F, Nahrstedt A, Schmidt M, Mansoor K. Polyphenols from Ginkgo biloba. Sci Pharm 2010; 78(4): 897-907.
[http://dx.doi.org/10.3797/scipharm.1003-19] [PMID: 21179324]
[26]
Al-kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Batiha GES. Ginkgo biloba in the management of the COVID‐19 severity. Arch Pharm 2022; 355(10): 2200188.
[http://dx.doi.org/10.1002/ardp.202200188] [PMID: 35672257]
[27]
Ibrahim MA, Ramadan HH, Mohammed RN. Evidence that Ginkgo biloba could use in the influenza and coronavirus COVID-19 infections. J Basic Clin Physiol Pharmacol 2021; 32(3): 131-43.
[http://dx.doi.org/10.1515/jbcpp-2020-0310] [PMID: 33594843]
[28]
Guimarães AP, de Souza FR, Oliveira AA, et al. Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox. Eur J Med Chem 2015; 91: 72-90.
[http://dx.doi.org/10.1016/j.ejmech.2014.09.099] [PMID: 25458183]
[29]
Sahoo AK, Augusthian PD, Muralitharan I, et al. In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs. Mol Divers 2022; 1-16.
[http://dx.doi.org/10.1007/s11030-022-10550-1] [PMID: 36331784]
[30]
Molecular Operating Environment (MOE). Montreal, Quebec, Canada: Chemical Computing Group Inc 2014.
[31]
Noor-E-Tabassum null, Das R, Lami MS, et al. Ginkgo biloba: A treasure of functional phytochemicals with multimedicinal applications. Evid Based Complement Alternat Med 2022; 2022: 8288818.
[http://dx.doi.org/10.1155/2022/8288818]
[32]
Kobus J, Flaczyk E, Siger A, Nogala-Kałucka M, Korczak J, Pegg RB. Phenolic compounds and antioxidant activity of extracts of Ginkgo leaves. Eur J Lipid Sci Technol 2009; 111(11): 1150-60.
[http://dx.doi.org/10.1002/ejlt.200800299]
[33]
Šamec D, Karalija E, Dahija S, Hassan STS. Biflavonoids: Important contributions to the health benefits of ginkgo (Ginkgo biloba L.). Plants 2022; 11(10): 1381.
[http://dx.doi.org/10.3390/plants11101381] [PMID: 35631806]
[34]
Okhti ZA, Abdalah ME, Hanna DB. Phytochemical structure and biological effect of Ginkgo biloba leaves: A review. Int J Pharmacol Res 2021; 13(2): 1138-43.
[35]
Gao H, Chen X, Li Y, et al. Quality evaluation of Ginkgo biloba leaves based on non-targeted metabolomics and representative ingredi-ent quantification. J Chromatogr B Analyt Technol Biomed Life Sci 2023; 1214: 123549.
[http://dx.doi.org/10.1016/j.jchromb.2022.123549] [PMID: 36481725]
[36]
Liu L, Wang Y, Zhang J, Wang S. Advances in the chemical constituents and chemical analysis of Ginkgo biloba leaf, extract, and phytopharmaceuticals. J Pharm Biomed Anal 2021; 193: 113704.
[http://dx.doi.org/10.1016/j.jpba.2020.113704] [PMID: 33157480]
[37]
Belwal T, Giri L, Bahukhandi A, Kewlani P, Bhatt I, Rawal R. Ginkgo biloba. Nonvitamin and Nonmineral Nutritional Supplements. Elsevier Inc 2018.
[38]
Bolton EE, Wang Y, Thiessen PA, Bryant SH. PubChem: Integrated platform of small molecules and biological activities. Annual Reports in Computational Chemistry. Elsevier 2008; pp. 217-41. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1574140008000121
[39]
Pence HE, Williams A. ChemSpider: An online chemical information resource. J Chem Educ 2010; 87(11): 1123-4.
[http://dx.doi.org/10.1021/ed100697w]
[40]
Williams AJ. Chemspider: A Platform for crowdsourced collaboration to curate data derived from public compound data-bases. Collaborative Computational Technologies for Biomedical Research. John Wiley & Sons, Ltd 2011; pp. 363-86.
[http://dx.doi.org/10.1002/9781118026038.ch22]
[41]
ChemSpider | Search and share chemistry, (n.d.). Available from: http://www.chemspider.com/ accessed April 3, 2022).
[42]
PubChem. PubChem, (n.d.). Available from: https://pubchem.ncbi.nlm.nih.gov/ (accessed March 30, 2020).
[43]
McNamara JP, Hillier IH. Semi-empirical molecular orbital methods including dispersion corrections for the accurate prediction of the full range of intermolecular interactions in biomolecules. Phys Chem Chem Phys 2007; 9(19): 2362-70.
[http://dx.doi.org/10.1039/b701890h] [PMID: 17492099]
[44]
Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 1996; 17(5-6): 490-519.
[http://dx.doi.org/10.1002/(SICI)1096-987X(199604)17:5/6<490:AID-JCC1>3.0.CO;2-P]
[45]
Fadlan A, Nusantoro YR. The effect of energy minimization on the molecular docking of acetone-based oxindole derivatives. JKPK 2021; 6: 69.
[http://dx.doi.org/10.20961/jkpk.v6i1.45467]
[46]
R.P.D. Bank. RCSB PDB - 2V54: Crystal structure of vaccinia virus thymidylate kinase bound to TDP, (n.d.). Available from: https://www.rcsb.org/structure/2V54 (accessed March 10, 2023).
[47]
R.P.D. Bank. RCSB PDB - 1E2G: Human thymidylate kinase complexed with ADP, TDP and a magnesium-ion, (n.d.). Available from: https://www.rcsb.org/structure/1E2G (accessed March 10, 2023).
[48]
RCSB Protein Data. Available from: www.rcsb.org Available from: https://www.rcsb.org/search (accessed November 1, 2020).
[49]
Soga S, Shirai H, Kobori M, Hirayama N. Use of amino acid composition to predict ligand-binding sites. J Chem Inf Model 2007; 47(2): 400-6.
[http://dx.doi.org/10.1021/ci6002202] [PMID: 17243757]
[50]
Verdonk ML, Taylor RD, Chessari G, Murray CW. Illustration of current challenges in molecular docking. Structure-Based Drug Discovery. SpringerLink 2007; pp. 201-21.
[http://dx.doi.org/10.1007/1-4020-4407-0_8]
[51]
Brooijmans N. Docking methods, ligand design, and validating data sets in the structural genomics era. Available from: oreil-ly.com/library/view/structural-bioinformatics-2nd/9781118210567/9781118210567_c27.xhtml
[52]
Lipinski CA. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol 2004; 1(4): 337-41.
[http://dx.doi.org/10.1016/j.ddtec.2004.11.007] [PMID: 24981612]
[53]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3-26.
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]
[54]
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002; 45(12): 2615-23.
[http://dx.doi.org/10.1021/jm020017n] [PMID: 12036371]
[55]
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7(1): 42717.
[http://dx.doi.org/10.1038/srep42717] [PMID: 28256516]
[56]
Qin J, Chen J, Peng F, et al. Pharmacological activities and pharmacokinetics of liquiritin: A review. J Ethnopharmacol 2022; 293: 115257.
[http://dx.doi.org/10.1016/j.jep.2022.115257] [PMID: 35395381]
[57]
Yamauchi S, Hayashi Y, Kirikihira T, Masuda T. Synthesis and antioxidant activity of olivil-type lignans, bioscience, biotechnology, and biochemistry J Nat Prod 2005; 65: 1479-85.
[http://dx.doi.org/10.1271/bbb.69.113]
[58]
Schumacher B, Scholle S, Hölzl J, Khudeir N, Hess S, Müller CE. Lignans isolated from valerian: Identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors. J Nat Prod 2002; 65(10): 1479-85.
[http://dx.doi.org/10.1021/np010464q] [PMID: 12398547]
[59]
Liu P, Pan S. Advance in study of ginkgolic acid contained in Ginkgo biloba preparations. Zhongguo Zhongyao Zazhi 2012; 37(3): 274-7.
[PMID: 22568222]
[60]
Boateng ID. A critical review of ginkgolic acids in Ginkgo biloba leaf extract (EGb): Toxicity and technologies to remove ginkgolic acids and their promising bioactivities. Food Funct 2022; 13(18): 9226-42.
[http://dx.doi.org/10.1039/D2FO01827F] [PMID: 36065842]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy